Try a new search

Format these results:

Searched for:

in-biosketch:true

person:dengf01

Total Results:

242


Alterations of PTEN Tumor Suppressor Gene in Lethal Prostate Cancer: A Comparative Study Using Chromogenic In Situ Hybridization and Immunohistochemistry [Meeting Abstract]

Deng, F-M; Wang, Y.; Wu, X.; Xu, W.; Mosquera, J. M.; Rubin, M.; Melamed, J.; Zhou, M.
ISI:000331502201232
ISSN: 0893-3952
CID: 855442

Molecular Classification of Prostate Cancer with Family History Based on PTEN and ERG Gene Status [Meeting Abstract]

Xu, W.; Wang, Y.; Deng, F-M; Wu, X.; Tang, L.; Ubaradka, S.; Birch, C.; Melamed, J.; Zhou, M.
ISI:000331502201431
ISSN: 0893-3952
CID: 855482

Incidence and Genetic Characteristics of Clear Cell Tububopapillary Renal Cell Carcinoma [Meeting Abstract]

Xu, W.; Deng, F-M; Melamed, J.; Zhou, M.
ISI:000331155801333
ISSN: 0023-6837
CID: 855512

Gleason Score 3+4=7 Prostate Cancer with Minimal Quantity of Gleason Pattern 4 on Needle Biopsy Is Often Associated with Low Risk Tumor [Meeting Abstract]

Deng, F-M; Huang, C. C.; Kong, M.; Xu, X.; Zhou, M.; Melamed, J.
ISI:000331502201233
ISSN: 0893-3952
CID: 855532

Alterations of PTEN Tumor Suppressor Gene in Lethal Prostate Cancer: A Comparative Study Using Chromogenic In Situ Hybridization and Immunohisochemistry [Meeting Abstract]

Deng, F-M; Wang, Y.; Wu, X.; Xu, W.; Mosquera, J. M.; Rubin, M.; Melamed, J.; Zhou, M.
ISI:000331155801135
ISSN: 0023-6837
CID: 855542

CHD1 Deletion in a Cohort of Castration-Resistant Prostate Cancer [Meeting Abstract]

Friedman, C. S.; Deng, F-M; Barbieri, C. E.; MacDonald, T.; Xu, W.; Melamed, J.; Rubin, M. A.; Mosquera, J. M.; Zhou, M.
ISI:000331155801161
ISSN: 0023-6837
CID: 855552

Molecular Classification of Prostate Cancer with Family History Based on PTEN and ERG Gene Status [Meeting Abstract]

Xu, W.; Wang, Y.; Deng, F-M; Wu, X.; Tang, L.; Ubaradka, S.; Birch, C.; Melamed, J.; Zhou, M.
ISI:000331155801334
ISSN: 0023-6837
CID: 855562

Prostate Biopsies with Discontinuous Cancer Involvement: Gap or No Gap? [Meeting Abstract]

Eze, O.; Xu, W.; Deng, F-M; Melamed, J.; Zhou, M.
ISI:000331502201243
ISSN: 0893-3952
CID: 855572

Gleason Score 3+4=7 Prostate Cancer with Minimal Quantity of Gleason Pattern 4 on Needle Biopsy Is Often Associated with Low Risk Tumor [Meeting Abstract]

Deng, F-M; Huang, C. C.; Kong, M.; Xu, W.; Zhou, M.; Melamed, J.
ISI:000331155801136
ISSN: 0023-6837
CID: 855592

A Prospective, Blinded Comparison of Magnetic Resonance (MR) Imaging-Ultrasound Fusion and Visual Estimation in the Performance of MR-targeted Prostate Biopsy: The PROFUS Trial

Wysock, James S; Rosenkrantz, Andrew B; Huang, William C; Stifelman, Michael D; Lepor, Herbert; Deng, Fang-Ming; Melamed, Jonathan; Taneja, Samir S
BACKGROUND: Increasing evidence supports the use of magnetic resonance (MR)-targeted prostate biopsy. The optimal method for such biopsy remains undefined, however. OBJECTIVE: To prospectively compare targeted biopsy outcomes between MR imaging (MRI)-ultrasound fusion and visual targeting. DESIGN, SETTING, AND PARTICIPANTS: From June 2012 to March 2013, prospective targeted biopsy was performed in 125 consecutive men with suspicious regions identified on prebiopsy 3-T MRI consisting of T2-weighted, diffusion-weighted, and dynamic-contrast enhanced sequences. INTERVENTION: Two MRI-ultrasound fusion targeted cores per target were performed by one operator using the ei-Nav|Artemis system. Targets were then blinded, and a second operator took two visually targeted cores and a 12-core biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Biopsy information yield was compared between targeting techniques and to 12-core biopsy. Results were analyzed using the McNemar test. Multivariate analysis was performed using binomial logistic regression. RESULTS AND LIMITATIONS: Among 172 targets, fusion biopsy detected 55 (32.0%) cancers and 35 (20.3%) Gleason sum >/=7 cancers compared with 46 (26.7%) and 26 (15.1%), respectively, using visual targeting (p=0.1374, p=0.0523). Fusion biopsy provided informative nonbenign histology in 77 targets compared with 60 by visual (p=0.0104). Targeted biopsy detected 75.0% of all clinically significant cancers and 86.4% of Gleason sum >/=7 cancers detected on standard biopsy. On multivariate analysis, fusion performed best among smaller targets. The study is limited by lack of comparison with whole-gland specimens and sample size. Furthermore, cancer detection on visual targeting is likely higher than in community settings, where experience with this technique may be limited. CONCLUSIONS: Fusion biopsy was more often histologically informative than visual targeting but did not increase cancer detection. A trend toward increased detection with fusion biopsy was observed across all study subsets, suggesting a need for a larger study size. Fusion targeting improved accuracy for smaller lesions. Its use may reduce the learning curve necessary for visual targeting and improve community adoption of MR-targeted biopsy.
PMID: 24262102
ISSN: 0302-2838
CID: 666702